"Cholangiocarcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant tumor arising from the epithelium of the BILE DUCTS.
| Descriptor ID |
D018281
|
| MeSH Number(s) |
C04.557.470.200.025.450
|
| Concept/Terms |
Cholangiocarcinoma- Cholangiocarcinoma
- Cholangiocarcinomas
- Cholangiocellular Carcinoma
- Carcinoma, Cholangiocellular
- Carcinomas, Cholangiocellular
- Cholangiocellular Carcinomas
Extrahepatic Cholangiocarcinoma- Extrahepatic Cholangiocarcinoma
- Cholangiocarcinoma, Extrahepatic
- Cholangiocarcinomas, Extrahepatic
- Extrahepatic Cholangiocarcinomas
Intrahepatic Cholangiocarcinoma- Intrahepatic Cholangiocarcinoma
- Cholangiocarcinoma, Intrahepatic
- Cholangiocarcinomas, Intrahepatic
- Intrahepatic Cholangiocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cholangiocarcinoma".
Below are MeSH descriptors whose meaning is more specific than "Cholangiocarcinoma".
This graph shows the total number of publications written about "Cholangiocarcinoma" by people in this website by year, and whether "Cholangiocarcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 7 | 0 | 7 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 5 | 0 | 5 |
| 2012 | 4 | 1 | 5 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 6 | 0 | 6 |
| 2018 | 3 | 1 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 4 | 2 | 6 |
| 2021 | 4 | 0 | 4 |
| 2022 | 4 | 0 | 4 |
| 2023 | 7 | 1 | 8 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholangiocarcinoma" by people in Profiles.
-
Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients. JCO Precis Oncol. 2025 Jan; 9:e2400712.
-
Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma. Liver Int. 2025 Jan; 45(1):e16208.
-
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma. Ann Oncol. 2025 Apr; 36(4):426-443.
-
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin Oncol. 2025 Feb 10; 43(5):536-544.
-
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling. Ann Oncol. 2025 Apr; 36(4):414-425.
-
DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Clin Epigenetics. 2024 Nov 10; 16(1):156.
-
Radiogenomics of Intrahepatic Cholangiocarcinoma: Correlation of Imaging Features With BAP1 and FGFR Molecular Subtypes. J Comput Assist Tomogr. 2024 Nov-Dec 01; 48(6):868-874.
-
Imaging cholangiocarcinoma: CT and MRI techniques. Abdom Radiol (NY). 2025 01; 50(1):94-108.
-
Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018-2023. Clin Mol Hepatol. 2024 Oct; 30(4):756-770.
-
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. Future Oncol. 2024; 20(36):2811-2822.